Created On: 2020-07-15
Record Count: 4
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7077
Biological Materials means the K6H6/B5 and /or 1D12 cell lines.
IPSCIO Record ID: 26654
IPSCIO Record ID: 27645
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5
4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas
5,286,647 – human-human hybridomas for neoplasms
5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.
5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.
6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions
6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
6,051,693 – CLNH11-specific antibodies
6,090,924 – human-human CLNH5-specific antibodies
6,165,467 – stabilized human monoclonal antibody preparation
The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company
IPSCIO Record ID: 211863
Pursuant to the third partys permission, for the nonexclusive license, Licensor grants the worldwide, nonexclusive right and license, with the right to sublicense, in the Field under the Patent Rights to make, have made, use, lease, sell, offer for sale and import the Licensed Products and to practice the Licensed Processes; to make, have made, use, lease, sell, offer for sale, import and create Modifications of the Biological Materials; and to use Know-How, and
For the exclusive license, Licensor grants the worldwide, exclusive right and license, with the right to sublicense, in the Field to make, have made, use, lease, sell, offer for sale and import Modifications.